Modulation of permeability and adhesion molecule expression by XXXX choroidal endothelial cells.

@entity1 @entity2995 @entity1940 @entity4725 @entity310 @entity379 @entity989 @entity2071 @entity1020
PURPOSE: The therapeutic potential of TA, an anti-inflammatory glucocorticoid, for the treatment of @entity989 has been examined in several independent clinical studies. The modulation of permeability and adhesion molecule expression of an epithelial cell line has been described in vitro, with the use of cytokines and @entity2995 (TA). In the current study, the influence of proinflammatory cytokines and TA on permeability and adhesion molecule expression in @entity1 choroidal endothelial cells (CECs) was investigated. METHODS: @entity1 CEC isolates treated with @entity379 , @entity310 , and TA were evaluated by flow cytometry and immunocytochemistry for expression of @entity2071 , @entity4725 , and major histocompatibility complex (MHC)-I and -II. The effects of @entity379 , @entity310 , and TA on paracellular permeability of CEC monolayers were assessed in transendothelial cell resistance (TER) assays. RESULTS: Both @entity379 and @entity310 significantly upregulated expression of @entity2071 and MHC-I on CECs. Expression of @entity4725 was induced after stimulation with both @entity379 and @entity310 , whereas expression of MHC-II was induced only by stimulation with @entity379 . Cytokine-induced expression of @entity2071 , MHC-I, and MHC-II antigen by CECs was significantly downregulated by TA. @entity379 stimulation also increased permeability of CEC monolayers, whereas subsequent TA treatment decreased permeability of CEC monolayers. CONCLUSIONS: @entity1 CEC isolates provide a useful in vitro model to study @entity1940 characteristics and their potential response to pro- and anti-inflammatory agents. In addition, the results indicate that TA has the capacity to reduce adhesion molecule expression and permeability of choroidal vessels in vitro, confirming its potential as a therapeutic agent for treatment of exudative @entity1020 .
